Entries by Uta Mommert

Virometix: US$15m for Synthetic Vaccines

Swiss biotech Virometix has raised US$15m in fresh funding to accelerate development of its lead pneumococcal vaccine candidate and advance its next-generation synthetic vaccine platform.

BioNTech Secures £129m UK Backing

BioNTech is set to open a research centre for cancer therapy in the United Kingdom, much to the delight of the British government, which is helping pave the way with a substantial financial boost.

SV Health Raises US$269m for Dementia Start-ups

British investment firm SV Health Investors has secured US$269m for its second fund, Dementia Discovery Fund, or DDF-2. The capital will be used to invest in companies developing or enabling novel therapeutics for dementia.

Yeast on the Final Frontier

A team led by Imperial College London has launched a miniature lab into Earth orbit to test the production of edible proteins in space with the help of yeast-based biotech.

Whey Waste Finds New Life as Protein

French dairy heavyweight Bel Group has teamed up with Standing Ovation in a bid to transform surplus whey from cheese production into high-value casein proteins using precision fermentation. The collaboration is set to address the longstanding issue of under-utilised acid whey, a by-product that often goes to waste in the dairy sector.

Gene therapy manufacturing: Fuse Vectors secures US$5.2m

Fuse Vectors has secured US$5.2m in pre-seed financing to revolutionise gene therapy manufacturing with its cell-free viral vector technology. The Danish company is aiming to make treatments more accessible and cost-effective by streamlining production.

Green Biotech Fund surges past €150M target

Dutch venture capital firm Forbion revealed that its BioEconomy Fund I has amassed €164.5m. This surpasses the fund’s initial target of €150m, highlighting the increasing interest from investors in the commercial viability of biotech solutions that tackle worldwide sustainability issues.